Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 41,110.7% in June

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 802,784 shares, a growth of 41,110.7% from the May 31st total of 1,948 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 182,658 shares, the short-interest ratio is presently 4.4 days.

Provectus Biopharmaceuticals Stock Performance

PVCT opened at $0.07 on Friday. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.10. The firm’s 50-day moving average price is $0.06 and its 200 day moving average price is $0.06.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.